1. Search Result
Search Result
Results for "

Ankylosing spondylitis

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

5

Inhibitory Antibodies

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0634

    COX Inflammation/Immunology
    Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac
  • HY-141535A

    Interleukin Related Infection Inflammation/Immunology
    IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
    IL-17 modulator 1 disodium
  • HY-109143B

    (R)-ABBV-105

    Btk Inflammation/Immunology Cancer
    (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .
    (R)-Elsubrutinib
  • HY-B0230
    Phenylbutazone
    1 Publications Verification

    COX Inflammation/Immunology
    Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone
  • HY-12385

    Others Inflammation/Immunology
    Ximoprofen is a propionic nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory property. Ximoprofen can be used for ankylosing spondylitis research .
    Ximoprofen
  • HY-127150

    Perclusone

    Others Inflammation/Immunology
    Clofezone (Perclusone) is a antirheumatic agent. Clofezone can be used in the study of various rheumatic diseases, especially arthritis (RA) and ankylosing spondylitis (AS) .
    Clofezone
  • HY-P99754

    Interleukin Related Inflammation/Immunology
    Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
    Netakimab
  • HY-B0634R

    COX Inflammation/Immunology
    Aceclofenac (Standard) is the analytical standard of Aceclofenac. This product is intended for research and analytical applications. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac (Standard)
  • HY-141535

    Interleukin Related Infection Inflammation/Immunology
    IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
    IL-17 modulator 1
  • HY-158159

    Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-B0230R

    COX Inflammation/Immunology
    Phenylbutazone (Standard) is the analytical standard of Phenylbutazone. This product is intended for research and analytical applications. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research .
    Phenylbutazone (Standard)
  • HY-W009706A

    Allopydin sodium; W-7320 sodium

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac sodium is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac sodium is a prostaglandin H2 synthase inhibitor. Alclofenac sodium can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac sodium
  • HY-W009706

    Allopydin; W-7320

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac (Allopydin) is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac is a prostaglandin H2 synthase inhibitor. Alclofenac can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac
  • HY-W009706B

    Allopydin (lysinate); W-7320 (lysinate)

    Prostaglandin Receptor Inflammation/Immunology
    Alclofenac lysinate is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac lysinate is a prostaglandin H2 synthase inhibitor. Alclofenac lysinate can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research .
    Alclofenac (lysinate)
  • HY-B0634S

    Isotope-Labeled Compounds COX Inflammation/Immunology
    Aceclofenac-d4 is the deuterium labeled Aceclofenac. Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis[1][2].
    Aceclofenac-d4
  • HY-P99652

    AK 111

    Interleukin Related Inflammation/Immunology
    Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
    Gumokimab
  • HY-P9927
    Secukinumab
    2 Publications Verification

    AIN457

    Interleukin Related Inflammation/Immunology Cancer
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
    Secukinumab
  • HY-B0230S2

    COX Inflammation/Immunology
    Phenylbutazone- 13C12 is the 13C12 labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research.
    Phenylbutazone-13C12
  • HY-P99335

    Anti-Human IL17A Recombinant Antibody

    Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
    Vunakizumab
  • HY-B0230S

    COX Inflammation/Immunology
    Phenylbutazone(diphenyl-d10) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].
    Phenylbutazone(diphenyl-d10)
  • HY-B0230S1

    Isotope-Labeled Compounds COX Inflammation/Immunology
    Phenylbutazone-d9 is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].
    Phenylbutazone-d9
  • HY-P99280
    Bimekizumab
    1 Publications Verification

    Anti-Human IL17A/IL-17F Recombinant Antibody

    Interleukin Related Inflammation/Immunology
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
    Bimekizumab
  • HY-B1138R

    COX Caspase Inflammation/Immunology
    Fenbufen (Standard) is the analytical standard of Fenbufen. This product is intended for research and analytical applications. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .
    Fenbufen (Standard)
  • HY-B1138
    Fenbufen
    1 Publications Verification

    CL-82204

    COX Caspase Inflammation/Immunology
    Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor .
    Fenbufen
  • HY-157139

    Carbonic Anhydrase Phosphatase Inflammation/Immunology
    ALP/Carbonic anhydrase-IN-1 (Compound 1e) is a dual carbonic anhydrase (CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonic anhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
    ALP/Carbonic anhydrase-IN-1
  • HY-15826
    SGC-CBP30
    Maximum Cited Publications
    13 Publications Verification

    Epigenetic Reader Domain Histone Acetyltransferase Inflammation/Immunology Cancer
    SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
    SGC-CBP30

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: